Watch BTMD. Know when insiders buy.
One email the day a filing lands. Free.
BTMD
biote Corp.
1.45
−0.06 −3.97%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
4
FLAG · shorts 4
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $84.4MP/E 13.2DIV YIELD —FCF YIELD 23.54%REV TTM $183.5M −7.8%NET INCOME $5.9M −81.3%NET DEBT $113.8M52W 1.30 – 3.45SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $44.2M | −9.5% | — | −$3.5M | −$6.6M | −306.1% | -0.23 | −$1.2M | $2.6M | −$3.7M | Aug 7 |
| Q1 2026 · Mar 31 | $44.9M | −8.3% | — | $3.2M | $2.3M | −83.4% | 0.06 | $3.9M | $362K | $3.5M | May 11 |
| Q4 2025 · Dec 31derived | $46.4M | −6.9% | — | $6.8M | $2M | −47.2% | 0.06 | $7.6M | $1.1M | $6.5M | Mar 13 |
| Q3 2025 · Sep 30 | $48M | −6.7% | — | $8.3M | $8.2M | −23.5% | 0.22 | $14.1M | $499K | $13.6M | Nov 7 |
| Q2 2025 · Jun 30 | $48.9M | −0.6% | — | $10.8M | $3.2M | — | 0.10 | $7.1M | $1.8M | $5.3M | Aug 7 |
| Q1 2025 · Mar 31 | $49M | +4.7% | — | $9.7M | $13.7M | — | 0.37 | $6.5M | $1.6M | $4.8M | May 11 |
| Q4 2024 · Dec 31derived | $49.8M | +9.0% | — | $2.8M | $3.7M | −52.1% | 0.11 | $12.4M | $1.7M | $10.7M | Mar 13 |
| Q3 2024 · Sep 30 | $51.4M | +12.8% | — | $12.2M | $10.7M | +42.1% | 0.33 | $15.6M | $1.6M | $14M | Nov 7 |
| Q2 2024 · Jun 30 | $49.2M | — | — | $6.2M | −$7.1M | — | -0.21 | $9.9M | $2.5M | $7.4M | Aug 8 |
| Q1 2024 · Mar 31 | $46.8M | — | — | $10.4M | −$4.2M | — | -0.12 | $7.4M | $704K | $6.7M | May 9 |
| Q4 2023 · Dec 31derived | $45.7M | — | — | $5.5M | $7.7M | — | 0.32 | $7M | −$159K | $7.1M | Mar 14 |
| Q3 2023 · Sep 30 | $45.6M | — | — | $7.6M | $7.5M | — | 0.24 | $160K | $451K | −$291K | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $192.2M | — | $35.6M | $27M | 14.1% | 0.74 | $35.2M | $5M | $30.2M | $3.4M | $1.7M |
| FY2024 · to Dec 31 | $197.2M | — | $31.6M | $3.2M | 1.6% | 0.09 | $45.2M | $6.4M | $38.8M | $5.6M | $4.7M |
| FY2023 · to Dec 31 | $185.4M | — | $28.7M | $3.3M | 1.8% | 0.13 | $26.9M | $359K | $26.5M | — | $8.7M |
| FY2022 · to Dec 31 | $165M | — | −$60.7M | −$969K | -0.6% | -0.12 | −$9.2M | $333K | −$9.5M | — | $12.9M |
| FY2021 · to Dec 31 | $139.4M | — | $34.6M | $11.1M | 8.0% | — | $33.7M | $1.4M | $32.3M | — | $11.4M |
Every number comes from biote Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.